The most widely used high-dose chemotherapy (HDC) before autologous stem cell transplant (ASCT) is BEAM regimen (carmustine, etoposide, cytarabine, and melphalan) [1, 2], which is considered the gold standard both in United States and Europe [3, 4]. However, carmustine has been often substituted by other molecules due to its difficult supplying and high costs [3, 5]. In Italy, the most frequently used alternative regimen is FEAM (fotemustine, etoposide, cytarabine, melphalan), in which carmustine is replaced by fotemustine, a third-generation chloroethyl-nitrosourea with ability to cross the blood–brain barrier and a more favorable pulmonary toxicity profile, however not available in all European countries [6]. Even though only two phase-2 studies have been until now published [7, 8], the Italian Regulatory Agency for medical products granted reimbursement of fotemustine by the National Health Service as component of FEAM regimen. Based on these considerations, we aimed to investigate in a retrospective study the comparison between BEAM and FEAM regimen in terms of efficacy and safety in lymphoma patients undergoing ASCT.

. BEAM vs FEAM conditioning: retrospective study in lymphoma patients undergoing autologous stem cell transplant / Marchesi, F.; Capria, S.; Giannarelli, D.; Trisolini, S. M.; Ansuinelli, M.; Caputo, M. D.; Serrao, A.; Gumenyuk, S.; Renzi, D.; Pupo, L.; Palombi, F.; Provenzano, I.; Di Rocco, A.; Pisani, F.; Romano, A.; Spadea, A.; Papa, E.; Canfora, M.; Cantonetti &, M.; Mengarelli, A.. - In: BONE MARROW TRANSPLANTATION. - ISSN 1476-5365. - (2018). [10.1038/s41409-018-0120-x]

. BEAM vs FEAM conditioning: retrospective study in lymphoma patients undergoing autologous stem cell transplant.

S. Capria;M. Ansuinelli;A. Serrao;A. Di Rocco;
2018

Abstract

The most widely used high-dose chemotherapy (HDC) before autologous stem cell transplant (ASCT) is BEAM regimen (carmustine, etoposide, cytarabine, and melphalan) [1, 2], which is considered the gold standard both in United States and Europe [3, 4]. However, carmustine has been often substituted by other molecules due to its difficult supplying and high costs [3, 5]. In Italy, the most frequently used alternative regimen is FEAM (fotemustine, etoposide, cytarabine, melphalan), in which carmustine is replaced by fotemustine, a third-generation chloroethyl-nitrosourea with ability to cross the blood–brain barrier and a more favorable pulmonary toxicity profile, however not available in all European countries [6]. Even though only two phase-2 studies have been until now published [7, 8], the Italian Regulatory Agency for medical products granted reimbursement of fotemustine by the National Health Service as component of FEAM regimen. Based on these considerations, we aimed to investigate in a retrospective study the comparison between BEAM and FEAM regimen in terms of efficacy and safety in lymphoma patients undergoing ASCT.
File allegati a questo prodotto
File Dimensione Formato  
Marchesi_BEAM-FEAM_2018.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 517.67 kB
Formato Adobe PDF
517.67 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/1416564
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact